ReviewCancers2025
Narrative Review of the Use of Genomic-Adjusted Radiation Dose (GARD) in Radiotherapy.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review examines the genomic-adjusted radiation dose (GARD), a biologically informed framework developed to personalize radiotherapy by integrating tumor-specific genomic data. GARD combines the radiosensitivity index (RSI), based on gene expression, with the linear quadratic model to estimate patient-specific radiation effect. Since its introduction in 2017, GARD has demonstrated prognostic value across multiple cancer types in retrospective studies. This review summarizes key studies evaluating GARD across various tumor types and clinical contexts. Emerging trials, including a Phase II trial in HPV-positive oropharyngeal cancer, aim to validate GARD-guided dosing in precision radiotherapy. Future efforts may focus on refining RSI, addressing tumor heterogeneity, and validating GARD-guided dosing in prospective settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.